BridgeMD
New treatment option for Spondylarthropathies
Official title Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment
ClinicalTrials.gov ID: NCT04540432
What this study is testing
- What it's testing
- Idiopathic juvenile arthritis includes 20% of patients with arthritis with enthesitis or juvenile spondyloarthropathy. This is treated with anti-inflammatory drugs and then followed by biotherapy with DMARDs (Drugs Modifying the Activity of Rheumatic Disease) if the former are insufficient.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 18
You may be able to join if
- Patients aged over 6 and under 17 years old (included).
- Patients diagnosed with arthritis with juvenile enthesitis according to the International League of Associations for Rheumatology (ILAR) criteria.
- Patients who haven't been treated by Methotrexate or biotherapy for at least 3 months.
- Patients who haven't been treated by cortisone for over a month.
- Patients whose parents have given written informed consent.
You likely can't join if
- Patients enrolled in another category 1 study or who have already taken part in a category 1 study within 3 months prior to inclusion.
- Patients who are within an exclusion period determined by another study.
See the full eligibility criteria
- Patients aged over 6 and under 17 years old (included).
- Patients diagnosed with arthritis with juvenile enthesitis according to the International League of Associations for Rheumatology (ILAR) criteria.
- Patients who haven't been treated by Methotrexate or biotherapy for at least 3 months.
- Patients who haven't been treated by cortisone for over a month.
- Patients whose parents have given written informed consent.
- Patients for whom the consent form has been signed by their legal guardian.
- Patients covered by the Social Security System or benefitting from private health insurance.
- Patients enrolled in another category 1 study or who have already taken part in a category 1 study within 3 months prior to inclusion.
- Patients who are within an exclusion period determined by another study.
The study team makes the final eligibility decision.
Where it's taking place
- Nîmes, Gard, France
- Montpellier, Hérault, France
- Marseille, France
- Toulouse, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nîmes, Gard, France; Montpellier, Hérault, France; Marseille, France; Toulouse, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.